This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kapoor D et al. (2000) Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 33: 308–312
Villeneuve JP et al. (2000) Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31: 207–210
Fontana RJ et al. (2002) Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123: 719–727
Manolakopoulos S et al. (2004) Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 99: 57–63
Perrillo R et al. (2004) Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126: 81–90
Acknowledgements
The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- ISHAK FIBROSIS SCORE
-
A score that grades liver histology according to the intensity of necroinflammatory activity, and stages the degree of fibrosis and architectural damage
- YMDD
-
Tyrosine–methionine–aspartate–aspartate motif in the catalytic domain of the viral polymerase/reverse transcriptase
- CHILD-PUGH SCORE
-
A scoring system used to evaluate prognosis of cirrhosis. Serum levels of bilirubin and albumin, prothrombin time, ascites, and encephalopathy are measured, and patients are divided into classes A (score 5–6), B (7–9) and C (10–15)
Rights and permissions
About this article
Cite this article
Karayiannis, P., Thomas, H. Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease?. Nat Rev Gastroenterol Hepatol 2, 138–139 (2005). https://doi.org/10.1038/ncpgasthep0118
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0118